Lactose-Gated Mesoporous Silica Particles for Intestinal Controlled Delivery of Essential Oil Components: An In Vitro and In Vivo Study
Metadatos
Mostrar el registro completo del ítemAutor
Poyatos Racionero, Elisa; González-Álvarez, Isabel; Sánchez Moreno, Paola; Sitia, Leopoldo; Gatto, Francesca; Paolo Pompa, Pier; Aznar, Elena; González Álvarez, Marta; Martínez Máñez, Ramón; Marcos, María Dolores; Bernardos, AndreaEditorial
MDPI
Materia
Essential oil components Mesoporous silica microparticles Controlled release Small intestine In vitro and in vivo intestinal models Lactase enzyme Molecular gates Enterocyte-like monolayers
Fecha
2021Referencia bibliográfica
Poyatos-Racionero, E.; González-Álvarez, I.; Sánchez-Moreno, P.; Sitia, L.; Gatto, F.; Pompa, P.P.; Aznar, E.; González-Álvarez, M.; Martínez-Máñez, R.; Marcos, M.D.; et al. Lactose-Gated Mesoporous Silica Particles for Intestinal Controlled Delivery of Essential Oil Components: An In Vitro and In Vivo Study. Pharmaceutics 2021, 13, 982. https://doi.org/10.3390/ pharmaceutics13070982
Patrocinador
Ministerio de Ciencia, Innovación y Universidades (Spanish Government) )the Agencia Estatal de Investigación (AEI) and European Union (projects RTI2018-100910-B-C41 and RTI2018-101599-B-C22-AR (MCIU/AEI/ FEDER, EU)); Ministerio de Universidades (Spanish Government) (BG20/00020, A.B. Beatriz Galindo contract); Agencia Estatal de Investigación and European Union through FEDER (Fondo Europeo de Desarrollo Regional, AEI/FEDER EU, project SAF2016-78756); Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana (project PROMETEO 2018/024 and E.P-R. predoctoral grant ACIF/2016/023)Resumen
Mesoporous silica microparticles functionalized with lactose for the specific release of
essential oil components (EOCs) in the small intestine are presented. In vitro and in vivo intestinal
models were applied to validate the microparticles (M41-EOC-L), in which the presence of lactase
acts as the triggering stimulus for the controlled release of EOCs. Among the different microdevices
prepared (containing thymol, eugenol and cinnamaldehyde), the one loaded with cinnamaldehyde
showed the most significant Caco-2 cell viability reduction. On the other hand, interaction of the
particles with enterocyte-like monolayers showed a reduction of EOCs permeability when protected
into the designed microdevices. Then, a microdevice loaded with cinnamaldehyde was applied in
the in vivo model of Wistar rat. The results showed a reduction in cinnamaldehyde plasma levels
and an increase in its concentration in the lumen of the gastrointestinal tract (GIT). The absence of
payload release in the stomach, the progressive release throughout the intestine and the prolonged
stay of the payload in the GIT-lumen increased the bioavailability of the encapsulated compound
at the site of the desired action. These innovative results, based on the specific intestinal controlled
delivery, suggest that the M41-payload-L could be a potential hybrid microdevice for the protection
and administration of bioactive molecules in the small intestine and colon.